Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Fineline Cube Sep 7, 2026
Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Fineline Cube Sep 7, 2026
Company Drug PIC

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

Fineline Cube Sep 7, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Fineline Cube Sep 7, 2026
Company Drug PIC

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Fineline Cube Aug 7, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its self-developed Class 1...

Company Drug PIC

Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19

Fineline Cube Aug 7, 2026

The Category 1 innovative drug Iscartrelvir, jointly developed by Westlake University, Westlake Laboratory, and Westlake...

Company Drug

Hengrui Pharmaceuticals Secures Third NMPA Approval for Trastuzumab Rezetecan in HER2-Positive Colorectal Cancer

Fineline Cube Aug 7, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HER2-targeting antibody-drug conjugate...

Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026

Biogen Inc. (NASDAQ: BIIB) announced the completion of its previously disclosed $1 billion acquisition of...

Company Drug

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Fineline Cube Aug 7, 2026

TransThera Sciences (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) has granted conditional...

Others PIC

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Fineline Cube Aug 7, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company PIC

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Fineline Cube Aug 6, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced second-quarter 2026 financial results with total revenues of USD...

Company PIC

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Fineline Cube Aug 6, 2026

Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of...

Company Drug PIC

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026

Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong)...

Others

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

Fineline Cube Aug 6, 2026

Luye Pharma Group Limited (HKG: 2186) announced that its independently developed new molecular entity LY03015...

Company

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Fineline Cube Aug 6, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half...

Company PIC

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance

Fineline Cube Aug 6, 2026

Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD...

Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of a Biologics License Application...

Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...

Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026

AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of...

Company R&D

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Fineline Cube Aug 6, 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM9077, an AI-powered, potential first-in-class Target Y...

Company PIC

BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance

Fineline Cube Aug 6, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q2 2026 financial results featuring...

Company PIC

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

Fineline Cube Aug 6, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of...

Posts pagination

1 … 12 13 14 … 717

Recent updates

  • HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
  • NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer
  • Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
  • Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
  • Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.